Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00298298 · ClinicalTrials.gov registry record · Phase 1
DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by AVAX Technologies.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00298298 is a Phase 1 study that was terminated before completion, run by AVAX Technologies. The registered enrollment target is 6 participants.
The verdict
NCT00298298, a Phase 1 study, was terminated before completion, sponsored by AVAX Technologies.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
To determine if a vaccine made from patient's own tumor tissue can stimulate an immune response against the patient's tumor cells. To determine the safety of the vaccine
Interventions
- BIOLOGICAL L-Vax: Autologous, DNP-Modified NSCLC Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-01 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00298298
The ClinicalTrials.gov registry entry for NCT00298298 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AVAX Technologies, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which L-Vax: Autologous, DNP-Modified NSCLC Vaccine is the first listed.
NCT00298298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00298298 about?
NCT00298298 is a clinical study titled "DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer". To determine if a vaccine made from patient's own tumor tissue can stimulate an immune response against the patient's tumor cells. To determine the safety of the vaccine
What is the current status of trial NCT00298298?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2006-01. Estimated completion is 2014-01.
What interventions are being tested in trial NCT00298298?
The interventions under investigation include: L-Vax: Autologous, DNP-Modified NSCLC Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00298298?
This trial is sponsored by AVAX Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.